

5/28/09

## William Brooks Gentry, M.D.

#3 Rivers Edge • Little Rock, AR • 72227 • (501) 228-0861

Professor • Department of Anesthesiology; Associate Professor • Dept. of Pharmacology & Toxicology  
Vice-Chair for Research • Department of Anesthesiology  
College of Medicine • University of Arkansas for Medical Sciences  
4301 W. Markham, Slot 515 • Little Rock, AR • 72205  
(501) 686-7611 • fax (501) 526-4618 • e-mail [gentrywilliams@uams.edu](mailto:gentrywilliams@uams.edu)  
Chief Medical Officer • InterveXion Therapeutics, LLC  
4301 W. Markham, Slot 831 • Little Rock, AR 72205

### EDUCATION

---

- 1988-94 Northwestern University, Northwestern Memorial Hospital; Chicago, IL  
\* Internship: Medicine  
\* Residency: Anesthesiology  
\* Fellowship: Clinical Pharmacology/Pharmacokinetics  
**Honors:** - Chief Resident, Department of Anesthesia  
- The H. Steele & Judith Holley Award in Academic Anesthesiology  
- The New York State Society of Anesthesiologists, Postgraduate Assembly Resident Research Contest, New York City, December 13, 1993, Finalist  
- Midwest Anesthesia Residents Conference, Columbia, MO, March, 1993; Second Place, Basic Sciences Division/Poster; Second Place, Clinical Sciences Division/Oral Presentation
- 1984-88 University of Arkansas, Little Rock, AR; **M.D.**,  
**Honors:** Freshman Oncology Fellowship; Buchanan Key, Jr/Sr.; Alpha Omega Alpha
- 1980-84 Hendrix College, Conway, AR, **B.A. with Distinction Biology**,  
**Honors:** Alpha Chi, Jr/Sr; Alpha Epsilon Delta, Honor Premedical Fraternity, Jr/Sr.

### BOARD CERTIFICATION

---

- 1993 Diplomate, American Board of Anesthesiology  
2005 Recertification, American Board of Anesthesiology's Maintenance of Certification in Anesthesiology Program

### EMPLOYMENT

---

- |              |  |                 |
|--------------|--|-----------------|
| 2006-present | University of Arkansas for Medical Sciences<br><i>Professor</i> , Dept. of Anesthesiology                        | Little Rock, AR |
| 2002-present | University of Arkansas for Medical Sciences<br><i>Vice Chair for Research</i> , Department of Anesthesiology     | Little Rock, AR |
| 2000-present | University of Arkansas for Medical Sciences<br><i>Associate Professor</i> , Dept. of Pharmacology and Toxicology | Little Rock, AR |
| 2000-2006    | University of Arkansas for Medical Sciences<br><i>Associate Professor</i> , Department of Anesthesiology         | Little Rock, AR |
| 1994-00      | University of Arkansas for Medical Sciences<br><i>Assistant Professor</i> , Department of Anesthesiology,        | Little Rock, AR |

1994	University of Arkansas for Medical Sciences <i>Instructor, Department of Anesthesiology</i>	Little Rock, AR
1992-94	Northwestern Univ., <i>Clinical Instructor, Dept. of Anesthesia</i> Northwestern Memorial Hospital, <i>Associate in Anesthesia</i> Veterans Affairs Lakeside Medical Center, <i>Staff Anesthesiologist</i>	Chicago, IL

## HONORS

---

1995	Runner Up, UAMS Department of Anesthesiology Golden Apple Award
1998, 2001, 2003, 2004, 2006, 2007	University of Arkansas for Medical Sciences, Red Sash Awards
2003, 2005, 2006, 2007, 2009	Best Doctors in America

## RESEARCH FUNDING

---

### *Current*

- National Institute on Drug Abuse (U01-DA 023900)  
 “Active Immunization for Treating Methamphetamine Abuse”  
 Role on Project: Co-I (5% effort; PI S. Michael Owens)
- National Institute on Drug Abuse (R01 DA 07610)  
 “Immunotherapy for Drug Abuse”  
 Role on Project: Co-I (5% effort; PI S. Michael Owens)
- National Institute on Drug Abuse (R42 DA 017596)  
 “Development of Plant Derived Antibodies for Drug Abuse”  
 Role on Project: UAMS PI (10% effort; Phase I/II Fast Track Small Business Technology  
 Transfer Award to InterveXion Therapeutics; Barry Holtz, PI)  
 7/1/04-6/30/10
- National Institute on Drug Abuse (R01 DA 10017)  
 “Opioid Antagonist Discrimination: A Model of Withdrawal”  
 Role on Project: Co-I (5% effort, PI, A Oliveto Beaudoin  
 4/1/06-3/31/11
- National Institute on Drug Abuse (R01 DA 026916)  
 “Monoamine Antagonist Therapies for Drug Abuse”  
 Role on Project: PI (25% effort)  
 9/1/09-7/31/12
- National Institute on Drug Abuse (RC2 DA 028915)  
 “Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity”  
 Role on Project: UAMS PI/Co-PI (25% effort; Grand Opportunities Grant to InterveXion  
 Therapeutics; R Barry Holtz, PhD, Co-PI)  
 9/30/09-8/31/11

### *Past*

- National Institute on Drug Abuse (R01 DA 11560)  
 “Antibody-based Therapy for Methamphetamine Abuse”  
 Role on Project: Co-I (10% effort; PI S. Michael Owens)  
 Total Direct Support: \$1,577,718 for 4/1/04 – 3/31/09 (NCE TO 3/31/10)

National Institute on Drug Abuse (P01 DA14361; Owens Program Project)

“Preclinical Testing of Antibody Therapy for METH Abuse”

Role on Project: **PI Component 3** entitled “Antibodies as Biological Interventions for Drug Abuse” (35% effort)

Total Direct Support: \$961,536 for 9/1/01 - 8/31/06; NCE thru 8/31/07

National Institute on Drug Abuse (R42 DA017596)

“Development of Plant Derived Antibodies for Drug Abuse”

Role on Project: **UAMS PI** (20% effort; Phase I/II Fast Track Small Business Technology Transfer Award to InterveXion Therapeutics; Barry Holtz, PI)

Total UAMS Direct Support: \$282,939 for 9/10/04– 6/30/06

National Institute on Drug Abuse (R01 DA014388)

“Behavioral Effects of GHB”

Role on Project: Co-I (5% effort; PI Alison Oliveto Beaudoin)

Total Direct Support: \$450,000; \$100,000 for 7/9/01 – 6/30/06 (NCE)

National Institute on Drug Abuse (K08 DA 00339)

“Mechanisms of Onset & Offset of Rapid Stimulant Effects”

Role on Project: PI (Mentored Clinician Scientist Award, S. Michael Owens, Mentor)

Total Direct Support: \$674,000 for 5/1/98 – 4/30/04

National Institute on Drug Abuse (R01 DA 07610)

“Immunotherapy for Drug Abuse”

Role on Project: Co-I (10% effort; PI S. Michael Owens)

Total Direct Support: \$1,056,665 for 4/1/95 – 3/31/99

National Institute on Drug Abuse (R01 DA 07610)

“Immunotherapy for Drug Abuse”

Role on Project: Co-I (10% effort; PI S. Michael Owens)

Total Direct Support: \$1,038,897 for 7/1/99 – 6/30/04

National Institute on Drug Abuse (R01 DA 11560)

“Antibody-based Therapy for Methamphetamine Abuse”

Role on Project: Co-I (10% effort; PI S. Michael Owens)

Total Direct Support: \$1,104,422 for 1/1/98 – 12/31/04

University of Arkansas for Medical Sciences, Pilot Study Committee

“Drug Disposition during Acute Aortic Occlusion and with Resumption of Flow”

Role on Project: PI

Total Direct Support: \$10,000 for 1/1/95 – 12/31/95

Society of Cardiovascular Anesthesiologists Starter Grant

“Drug Disposition during Acute Aortic Occlusion and with Resumption of Flow”

Role on Project: PI

Total Direct Support: \$10,000 for 1/1/95 – 12/31/95

University of Arkansas Foundation Board, Medical Research Endowment

“Drug Disposition with Distal and Proximal Aortic Occlusion”

Role on Project: PI

Total Direct Support: \$8,000 for 1/1/95 – 12/31/96

## INVITED SPEAKER:

- 
- 9/27/99 National Institute on Drug Abuse, 25<sup>th</sup> Anniversary Celebration; Bethesda, MD: "Immunotherapy for Drug Abuse"
- 1/24/01 UAMS Dept. of Pharmacology and Toxicology Seminar Series: "The Effect of Drug Administration Rate on the Mechanisms and Actions of Rapidly Acting Drugs"
- 7/22/03 University of Arkansas for Medical Sciences, Dean's Research Forum: "Pain, Peds, Premeds and Proteins: Pharmacology Research in the Department of Anesthesiology"
- 3/21/03 Arkadelphia, AR Noon Rotary Club: "Methamphetamine: Moonshine of the Millenium? Or Worse?"
- 9/22/04 University of Arkansas Systems Strategic Policy Forum; Little Rock, AR: "Inflexion Therapeutics: Focused on Protective Therapy"
- 7/27/04 University of Arkansas for Medical Sciences, Dean's Research Forum: "Mice to Rats to Plants to Humans: A Recipe for using NIH Support to Make Medicines"
- 9/23/04 Northwestern University Annual Founder's Day Lectures; Chicago, IL: "Passive Immunization for Drug Abuse: Targeting the Drug, Not the Receptor"
- 9/24/04 Northwestern University Annual Founder's Day Lectures; Chicago, IL: "Methamphetamine 'Farmacology': New Treatments for an Old Problem"
- 4/12/05 Arkadelphia (AR) Sunrise Rotary: InterveXion Therapeutics, LLC: A New Arkansas Company"
- 11/9/05 UAMS Dept. of Pharmacology and Toxicology Seminar Series: "Translating Preclinical Findings into Clinical Trials for a Monoclonal Antibody Medication to Treat Drug Abuse"
- 2/8/06 Central Arkansas Professional Coders; Little Rock, AR: "New Medications for Drug Abuse."
- 5/2/06 Entergy Lake Catherine Plant; Jones Mill, AR: "New Medications for Drug Abuse."
- 6/29/06 Central AR District, AR Dental Society, Little Rock, AR: "Meth Mouth and Other Maladies."
- 2/13/07 University of Arkansas, Fayetteville, Upper Level Medications Development Seminar. "Endpoints in Clinical Testing and Human Trials"
- 2/19/08 University of Arkansas, Fayetteville, Upper Level Medications Development Seminar. "Endpoints in Clinical Testing and Human Trials"
- 1/7/09 West Little Rock Rotary Club, Little Rock, AR. "New Medications for Drug Abuse."

## EDUCATIONAL ACTIVITIES:

*Current*

- 
- 1997 - present Lecturer, Sophomore Medical Pharmacology, University of Arkansas for Medical Sciences, College of Medicine (approximately 6 lecture hours per year)
- 1995 – present Lecturer, UAMS Department of Anesthesiology, General Pharmacology Section (approximately 4-6 lecture hours per year)

*Other Courses Taught*

- 1992-94 Co-Moderator, Dept. of Anesthesia, Northwestern University, Monthly Journal Club, Chicago, IL

- 1992 Instructor, Fiberoptic Intubation Workshop for Residents, S.J. Childers, M.D., Director, Chicago, IL
- 1993 Instructor, Fiberoptic Intubation Workshop, Midwest Anesthesia Conference, Andranik Ovassapian, M.D., Director, Chicago, IL

*Residents, Graduate Students, Medical Students (past and present)*

Faculty Advisor UAMS Anesthesiology Residents:

Boris Prakhina (1996), Jon Connelley and Mumtaz Alam (1997), Travis DeFreese (1998), Darin Wewers (1998), Carol McCourt (1999), Panchaprakesan Haran (2000), Gregorz Pitas (2001), Ahmed Munir (2003), Val Vlasie (2003), Julio Olaya (2003), Jason Parker (2004), Lee Arthur (2004), Yassar Aboul-Azm (2005), David Spann (2005), Carmen Keith (2008), Ronald Tilley (2009), Thea Rosenbaum (2011), Christian Savoie (2012)

Faculty Advisor UAMS Medical Students:

Larry Graham (1998), Jill McCollum (1999), McCall Hogan (2000), Marshall Newcity (2000), Shane Hardin (2000), Rush Simpson (2000), David Spann (2001), David Tyler (2001), Brian Kendall (2002), Patrick Williams (2002), Scott Jones (2002), Terry Fletcher (2003), Jan Alexander (2003), Ryan Roberts (2003), Eric Royster (2003); Adriana McGarrity (2004), Michael Cook (2004), Luke Thielken (2004), Carmen Keith (2004), Marc Wise (2004), Kristen Lienhart (2005), Ronald Tilley (2005), Joshua Chance (2006), Jeremy Bush (2006), Melissa Hughes (2006), Lloyd Meeks (2006), Michael Reding (2006), Robin Besancon (2007), Lydia Fann (2007), Monica Dixon (2007), Deborah Moss (2008), Matthew Sponn (2008), Jill Irby (2008), Josh Dilley (2009), Ida Mehdizadegan (2009), Drew Rogers (2010), Kurt Messer (2010), Jennifer Gray (2010)

Ph.D. Committee Member:

- Kelly Byrnes (2001), UAMS Department of Pharmacology and Toxicology
- Alessandra Milesi-Halle (2005), UAMS Dept. of Pharmacology & Toxicology
- Sarah G. White (2008), UAMS Department of Pharmacology and Toxicology
- Jonathan Hubbard (2008), UAMS Department of Pharmacology and Toxicology
- Michael Hambuchen (2011?), UAMS Department of Pharmacology and Toxicology
- Will Atchley (2011?), UAMS Department of Pharmacology and Toxicology

Ed.D. Committee Member: Timothy Atkinson (2006), Univ. of Arkansas at Little Rock

K25 Advisory Committee: Howard Hendrickson, Ph.D. "PK-PD Models: the Role of metabolites in drug actions"; (2004-05)

ADMINISTRATIVE DUTIES:

---

*UAMS*

*Current*

- Chair, UAMS Committee on Clinical Research 2009 - present
- Member, UAMS Senior Advisory Council 2009 - present
- Co-Chairman, Department of Anesthesiology Research Committee; 1996 – present
- Member, Department of Anesthesiology Chairman's Advisory Committee; 1999 – present
- Member, Department of Anesthesiology Clinical Competence Committee; 1994 – present

- Member, Department of Anesthesiology Clinical Incentive Program Committee; 1999 – present
- Member, Department of Anesthesiology Faculty Promotion Committee; 2000 – present
- Member, Department of Anesthesiology Resident Selection Committee; 1994 – present
- Member, Department of Anesthesiology Mock Oral Board Examination Committee; 1994 – present
- Member, UAMS Committee on Clinical Research; 2006 - present
- Member, Department of Anesthesiology Simulation Committee; 2006 - present

*Past*

- 1994-98: Associate Director, Anesthesiology Residency Program
- 1994-98; Co-Chairman, UAMS Department of Anesthesiology Peer Review and Evaluation Committee
- 1994-98: Co-Chairman, UAMS Department of Anesthesiology Resident Selection Committee
- 1994-98: Member, University Hospital Pharmacy and Therapeutics Committee
- 1995-98: Member, University Hospital Institutional Animal Use and Care Committee
- 1996: Member, University of Arkansas for Medical Sciences Clinical Trials Steering Committee
- 1999-02: Member, Graduate Medical Education Internal Review Subcommittee
- 2002-03: Member, UAMS HIPAA for Research Policy Committee
- 2002-03: Member, UAMS Research CQI Advisory Committee

*National**Current*

- Oral Examiner, American Board of Anesthesiologists 2008 to present
- Editorial Board, American Society of Anesthesiologists, Self Evaluation and Education Program, effective February 2004
- Medical Editor, American Society of Anesthesiologists, Self-Evaluation and Education Program, effective February 2009

*Past*

- 1998-01: Question Writer, American Board of Anesthesiologists
- 1998-04: Question Writer, American Society of Anesthesiologists, Self Evaluation and Education Program
- 1999-03: Member, American Society of Anesthesiologists Drug Disposition and Anesthetic Action Subcommittee
- Junior Editor, American Board of Anesthesiologists, 2003 to 2007
- Member, Ad Hoc Consultant Committee for the Division of Treatment Research and Development, National Institute on Drug Abuse, 2002 to present
- Member, Advisory Board to University of Arkansas, Fayetteville, NSF funded project “Studio Concept to Enable Students to Uncover the Rules of Nature at the Small Scale” (NSF-CHE-0418950) Don Bobbitt, Ph.D., PI
- 5/15/08 Invited Telereview NIDA Special Emphasis Panel ZDA 1 GXM-A07 Drug Interactions

**PROFESSIONAL SOCIETIES:**

- 
- American Society of Anesthesiologists, July 1992 - present

- Illinois Society of Anesthesiologists, July 1992 - March 1994
- International Anesthesia Research Society, January 1993 - present
- American Society for Clinical Pharmacology and Therapeutics, May 1994 - present
- Arkansas Society of Anesthesiologists, May 1994 - present
- Society of Cardiovascular Anesthesiologists, Sept 1994 - present
- Society for Ambulatory Anesthesia, January 1997 - present.
- American Society of Pharmacology and Experimental Therapeutics, March 1999 – present
- American Medical Association, 2002 - present
- College on Problems in Drug Dependence, 2007 - present

#### JOURNAL REVIEWER:

---

- *The Journal of Pharmacology and Experimental Therapeutics*
- *Anesthesia and Analgesia*
- *Clinical Pharmacokinetics*
- *Drug Metabolism Reviews*
- *Drug Metabolism and Disposition*
- *Journal of General Internal Medicine*

#### SCIENTIFIC PAPERS:

---

1. **Gentry WB** and Shanks CA: Reevaluation of a maneuver to visualize the anterior larynx after intubation. *Anesth Analg* 77: 161-163, 1993.
2. Shanks CA, Avram MJ, Krejcie TC, Henthorn TK, and **Gentry WB**: A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental. *J Pharmacokinet Biopharm* 21: 309-321, 1993.
3. **Gentry WB**, Krejcie TC, Henthorn TK, Shanks CA, Howard, KA, and Gupta DK, Avram MJ: Infusion rate-related thiopental dose-response relationships: Assessment of a pharmacokinetic-pharmacodynamic model. *Anesthesiology* 81:316-324, 1994.
4. **Gentry WB**, Krejcie TC, Henthorn TK, and Avram MJ: Induction and maintenance of anesthesia in dogs with intravenous administration of methohexital. *Am J of Vet Res.* 57(7):1044-1049, 1996.
5. Krejcie TC, Henthorn TK, Niemann CU, Klein C, Gupta DK **Gentry WB**, Shanks CA, and Avram MJ: Recirculatory pharmacokinetic models of markers of blood, extracellular fluid, and total body water administered concomitantly. *J Pharmacol Exp Ther.* 278(3):1050-1057, 1996.
6. Avram **MJ**, Krejcie TC, Niemann CU, Klein C, **Gentry WB**, Shanks CA, and Henthorn TK: The effect of halothane on the recirculatory pharmacokinetics of physiological markers. *Anesthesiology* 87:1381-1393, 1997.
7. Krejcie TC, Avram MJ, **Gentry WB**, Niemann CU, Janowski MP, and Henthorn TK: A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs. *J Pharmacokinet Biopharm* 25:169-190, 1997.
8. Proksch JW, **Gentry WB**, and Owens SM. Pharmacokinetic mechanisms for obtaining high renal co-elimination of phencyclidine and a monoclonal anti-phencyclidine antigen-binding fragment of immunoglobulin G in the rat. *J Pharmacol Exp Ther* 287:616-624, 1998.
9. Dalton, C, Jilka J, and **Gentry, WB**. Efficacy of phenergan suppositories dispensed to outpatient surgical patients in the recovery room. *Yale J Biol Med*, 71:391-395 1999.

10. Rivière GJ, Byrnes KA, **Gentry WB**, and Owens, SM. Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. *J Pharmacol Exp Ther.* 291:1220-1226, 1999.
11. Krejcie TC, Henthorn TK, **Gentry WB**, Niemann CU, Enders-Klein C, Shanks CA, and Avram MJ. Modifications of blood volume alter the disposition of markers of blood volume, extracellular fluid, and total body water. *J Pharmacol Exp Ther.* 291:1308-1316, 1999.
12. Proksch JW, **Gentry WB**, and Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. *J Pharmacol Exp Ther.* 292:831-837, 2000.
13. Rivière GJ, Gunnell MB, **Gentry WB**, and Owens, SM. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. *J Pharmacol Exp Ther.* 292:1042-1047, 2000.
14. Proksch JW, **Gentry WB**, and Owens SM. The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis and serum. *Drug Metab Disp* 28:742-747, 2000.
15. Arora H, Owens SM, and **Gentry WB**. Intravenous (+)-methamphetamine causes complex dose-dependent physiologic changes in awake rats. *Eur J Pharmacol.* 426(1-2):81-87, 2001
16. Ghafoor AU, Mayhew JF, **Gentry WB** and Schmitz ML. Transpleural Subclavian Central Venous Line Placement in a Child with Scoliosis Discovered During a Thoracotomy. *J Clin Anesth* 15:142-144, 2003
17. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, **Gentry WB**, Ang CYW, Cui Y. Cytochrome P-450 Phenotypic Ratios for Predicting Herb-Drug Interactions. *Clinical Pharmacology and Therapeutics* 72(3): 276-287, 2002
18. Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, **Gentry WB**, Landes RD, and Owens SM. Pharmacodynamic Mechanisms of Monoclonal Antibody-based Antagonism (+)-Methamphetamine in Rats. *Eur J Pharmacol* 461(2003) 119-128.
19. Laurenzana EM, Gunnell MG, **Gentry WB** and Owens SM: Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. *J Pharmacol Exp Ther* 306:1092-98; 2003.
20. Laurenzana EM, Byrnes-Blake KA, Milesi-Halle A, **Gentry WB**, Williams DK and Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. *Drug Metab Dispos.* 2003 Nov;31(11):1320-6.
21. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, **Gentry WB**, Carrier J, Khan IA, Edwards DJ, and Shah A. In Vivo Assessment of Botanical Supplementation on Human Cytochrome P450 Phenotypes: Citrus Aurantium, Echinacea purpurea, Milk Thistle, and Saw Palmetto. *Clin Pharmacol Ther* 76:428-440, 2004
22. **Gentry WB**, Ghafoor AU, Wessinger WD, Laurenzana EM and Owens SM. Route of Administration Changes (+)Methamphetamine Route of Administration Affects the Outcome of Pharmacological Studies in Rats. *Pharmacol Biochem Behav.* 2004 Vol 79/4 pp 751-760
23. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, **Gentry WB**, Khan IA, and Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. *Clin Pharmacol Ther* 2005; 77:415-26
24. Gurley BJ, Gardner SF, Hubbard MA, Williams DK **Gentry WB**, Cui Y and Ang CYW. Clinical Assessment of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly: St John's Wort, Garlic Oil, Panax Ginseng and Ginkgo Biloba, *Drugs & Aging*, 2005, 22(6):525-539
25. Milesi-Halle A, Hendrickson HP, Laurenzana EM, **Gentry WB** and Owens SM. Sex- and Dose-Dependency in the Pharmacokinetics and Pharmacodynamics of (+)-Methamphetamine and its

- Metabolite (+)-Amphetamine in Rats. *Toxicology and Applied Pharmacology*, 2005, 209(3):203-213
26. Byrnes-Blake KA, Laurenzana EM, Landes RD, **Gentry WB** and Owens SM. Monoclonal IgG Affinity and Treatment Time Alters Antagonism of (+)-Methamphetamine Effects in Rats. *Eur J Pharmacol*, 2005, 521:86-94.
  27. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, **Gentry WB**, Breen P, Carrier DJ and Cheboyina S. Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A4 Activity: Comparison of Milk Thistle and Black Cohosh to rifampin and Clarithromycin. *J Clin Pharmacol*, 46:201-213; 2006
  28. **Gentry WB**, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, and Owens SM. Safety and Efficiency of an Anti-(+)-Methamphetamine Monoclonal IgG in the Protection against Cardiovascular and Central Nervous System Effects of (+)-Methamphetamine in Rats. *International Immunopharmacology*, 6(2006) 968-977.
  29. Pitas G, Laurenzana EM, Williams DK, Owens SM, and **Gentry WB**. Anti-PCP Monoclonal Antibody Binding Capacity is not the Only Determinant of Effectiveness, Disproving the Concept that Antibody Capacity is easily Surmounted. *Drug Metab Dispos*, 2006 34:906-912.
  30. Meta G, Ghaleb A, **Gentry WB**, and Firnhaber J. Intrathecal therapy-associated masses. *Anesth Analg* 2006;103(1):260-1.
  31. Kumar P, **Gentry WB**, Arora H. Ultrasound Guidance in Regional Anesthesia, *J Anaesth Clin Pharmacol* 2007;23(2):121-8
  32. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, **Gentry WB**, Tong Y. Supplementation with goldenseal (*Hydrastis canadensis*) but not kava kava (*Piper methysticum*) inhibits human CYP3A activity in vivo. *Clin Pharmacol Ther*. 2008; 83(1): 61-69
  33. **Gentry WB**, Rüedi-Bettschen D, Owens SM. Development of Active and Passive Human Vaccines to Treat Methamphetamine Addiction. *Human Vaccines* 2009 5(4):1-8.
  34. McGaugh J, Mancino MJ, Feldman Z, Chopra MP, **Gentry WB**, Cargile C, and Oliveto A. Open Label Pilot Study of Modafinil for Methamphetamine Dependence. *Journal of Clinical Psychopharmacology* 2009;29(5):488-91.
  35. White SJ, Laurenzana EM, **Gentry WB**, Hendrickson HP, Williams DK, Ward KW, and Owens SM. Vulnerability to (+)-Methamphetamine Effects and the Relationship to Drug Disposition in Pregnant Rats during Chronic Infusion. *Toxicological Sciences* 2009;111(1):27-36.
  36. Laurenzana EM, Hendrickson HP, Carpenter D, Peterson EP, **Gentry WB**, West M, Che Y, Carroll FI, and Owens SM. Functional and Biological Determinants Affecting the Duration of Action and Efficacy of Anti-(+)-methamphetamine Monoclonal Antibodies in Rats. *Vaccine* 2009 in press

---

**BOOK CHAPTER:**

**Gentry WB** and Henthorn TK. Pharmacology of the Barbiturates. in "Intravenous Anesthesia", White PF (Ed). Williams and Wilkins, Baltimore, 1997.

---

**LETTER TO THE EDITOR**

Meta G, Ghaleb A, **Gentry WB** and Firnhaber J. Intrathecal Therapy-Associated Masses. *Anesth Analg* 2006; 103(1)260-1

---

**SELECTED PRESS RELEASES RELATED TO RESEARCH:**

8/1/04: "UA Team's Tobacco Snags Meth in Blood" by Eric Hand in the Arkansas Democrat-Gazette

- 1/27/05: Press Conference sponsored by UAMS announcing the funding NIDA grant R42 DA017596, “Development of Plant Derived Antibodies for Drug Abuse” to InterveXion Therapeutics; attended by Channels 4, 7, 11, 16, AETN; the Arkansas Democrat-Gazette; radio station KUAR (NPR); Featured on TodaysTHV.com
- 1/28/05: “Grant awarded for drug to combat PCP addiction” by Nell Smith in the Arkansas Democrat-Gazette
- 1/28/05: Similar related articles in the Hope Star, Harrison Daily Times, Batesville Daily Guard
- 1/28/05: Interview on KUAR/NPR public radio on the press conference
- 2/13/05: UAMS College of Medicine Buzz: “UAMS BioVentures’ Startup Company Awarded \$3M to Test Treatment for Drug Addiction”
- 2/15/05: participation in “Yesterday, Today and Tomorrow – Substance Abuse”; a weekly discussion show on KUAR/NPR; Phil Mariage, host
- 2/18/05: participation in Pat Lynch Show on KABZ radio, 103.7 FM
- 3/7/05: Talk Business Monthly article on InterveXion and the STTR by Roby Brock
- 6/1/05: “Arkansas, Canada firms to co-develop antibody”: a news brief in the Arkansas Democrat-Gazette announcing the partnership of Medicago and InterveXion Therapeutics to develop antibody therapeutics
- 7/06: “Bioventures from UAMS are Boosting State’s Economy” and “Arkansas Success Stories in the Making: UAMS Bioventures Graduate Company Capsules”. By Jeremy Pappas in Medical News of Arkansas.
- 12/5/06: Interviewed for “Arkansas’ Brighter Future: Education = Economic Development”; produced by the AR Dept. of Economic Development. Broadcast 12/5/07 KTHV TV, Little Rock, AR
- 5/16/08: Featured Investigator in UAMS Research News V 2 I9
- 6/08: Research Reviewed in ‘Housecalls’ a UAMS publication in an article entitled “An Injection of Hope”

#### PUBLISHED ABSTRACTS/PRESENTATIONS:

- Gentry WB** and Shanks CA: Confirming tracheal intubation: A simple maneuver revisited. *Anesthesiology* 77:A1064, 1992.
- Gentry WB**, Krejcie TC, Henthorn TK, Howard KA, Gupta DK, Shanks CA, and Avram MJ: Thiopental dose requirements with different rates of infusion. *Clin Pharmacol Ther* 53:218, 1993.
- Henthorn TK, Krejcie TC, Gupta DK, Shanks CA, **Gentry WB**, and Avram MJ: Recirculatory kinetics of ICG, inulin, and antipyrine. *Clin Pharmacol Ther* 53:217, 1993.
- Gentry WB**, Krejcie TC, Henthorn TK, Shanks CA, Gupta DK, and Avram MJ: Infusion rate-related thiopental dose-response: Application of a kinetic-dynamic model. *Anesthesiology* 79:A339, 1993.
- Gentry WB**, Henthorn TK, Krejcie TC, Gupta DK, Shanks CA, and Avram MJ: Recirculatory kinetics of markers of blood, interstitial fluid, and total body water administered concomitantly. *Anesthesiology* 79:A338, 1993.

- Avram MJ, Krejcie TC, Shanks CA, **Gentry WB**, Janowski MP, and Henthorn TK: The effect of halothane anesthesia on drug disposition from the moment of injection. *Anesthesiology* 79:A337, 1993.
- Henthorn TK, Krejcie TC, **Gentry WB**, Gupta DK, and Avram MJ: Inclusion of pulmonary uptake in a recirculatory model of lidocaine. *Anesthesiology* 79:A340, 1993.
- Krejcie TC, Henthorn TK, **Gentry WB**, Tulloch JM, Enders CL, and Avram MJ: The concordance of the early distribution kinetics of antipyrine and thiopental. *Anesthesiology* 79:A341, 1993.
- Shanks CA, Avram MJ, Krejcie TC, Henthorn TK, and **Gentry WB**: A kinetic-dynamic model for quantal responses with thiopental. *Anesthesiology* 79:A342, 1993.
- Krejcie TC, Henthorn TK, **Gentry WB**, Shanks CA, Enders C, Van Drie J, and Avram MJ: The effect of altered blood volume on intravascular mixing. *Anesthesiology* 81; A410, 1994.
- Henthorn TK, Krejcie TC, **Gentry WB**, and Avram MJ: The pulmonary uptake of alfentanil and fentanyl defined in a recirculatory model. *Anesthesiology* 81; A411, 1994.
- Gentry WB**, Wood SL, and Kennedy RL. Recirculatory kinetics of inulin during and following acute aortic occlusion in dogs. *Anesth Analg* 82:SCA124, 1996.
- Gentry WB**, Krejcie TC, Henthorn TK, and Avram MJ. Induction and maintenance of anesthesia in dogs with intravenous administration of methohexital. *Vet Digest* 1997.
- Gentry WB**. Aortic occlusion changes inulin tissue kinetics. *Clin Pharmacol Ther.* 61(2): 188, 1997.
- Gentry WB**, Valentine JL, and Owens SM. Phencyclidine (PCP) plasma kinetics poorly predict brain equilibration rate. *Clin Pharmacol Ther.* 61(2): 189, 1997.
- Gentry WB**, Proksch JW, and Owens SM. Phencyclidine (PCP) distribution in rats: Unique time profiles of brain and testes accumulation. *Clin Pharmacol Ther.* 65(2):155, 1999.
- Gentry WB** and Walker BL. Postoperative pain with knee arthroscopy: Efficacy of intraarticular morphine or meperidine in combination with local anesthetics. *Anesthesiology* 91(3A): A41, 1999.
- Gentry WB**, Proksch JW and Owens SM. The effect of anti-phencyclidine antibodies on the distribution of phencyclidine (PCP), a ketamine analogue, in rats. *Anesthesiology* 91(3A): A446, 1999.
- Arora H, Owens SM and **Gentry WB**. Time to Peak Hemodynamic Effects Increases with Increasing Intravenous Methamphetamine Doses in Rats. *Anesthesiology* 93(3A): A596, 2000.
- Arora H, Owens SM and **Gentry WB**. Methamphetamine Causes a Biphasic Temperature Response with High Intravenous Doses in Rats. *Anesthesiology* 93(3A): A667, 2000.
- Laurenzana EM, Woods SL, Gunnell MG, **Gentry WB** and Owens SM. Dose Response Relationships for Anti-PCP Monoclonal Antibodies. *FASEB Journal* 15(4):A225, 2001.
- Gurley, BJ, Gardner SF, Hubbard MA, **Gentry WB**, and Williams DK. Clinical Assessment of Potential Cytochrome P450-Mediated Herb-Drug Interactions. Presented at the Am Assoc of Pharmaceutical Scientists Meeting November 1, 2000 Indianapolis
- Laurenzana EM, Ali SF, **Gentry WB**, and Owens SM. Monoclonal Anti-Phencyclidine (PCP) IgG Produces Long Term Protection Against Adverse Effects of PCP. *The Toxicologist*, 66:1, Abstract 1221, p250, 2002
- Owens SM, Byrnes-Blake KA, Laurenzana EM, **Gentry WB**, Carroll FI, and Abraham P. Pharmacokinetic and Behavioral Mechanisms of Antibody-based Antagonism in a Model of Chronic (+)-Methamphetamine Use in Rats. *Drug and Alcohol Dependence* 66:S499, 2002
- Gentry WB**, Gardner SF and Gurley BJ. St. John's Wort Induces CYP 2E1 in Humans. *Anesthesiology* 2002; 96: A441
- Pitas G, Laurenzana EM, Owens SM, and **Gentry WB**. Single Dose anti-PCP IgG Alters Tissue Distribution of Bolus PCP doses During a Continuous, High-Dose PCP Infusion in Rats. *Clinical Pharmacology and Therapeutics* 2003; 73(2):P78.

- Gentry WB**, Laurenzana EM, Terlea T, Berg RJ, West JR, and Owens SM. Monoclonal anti-(+)methamphetamine ((+)METH) IgG reduces hemodynamic effects of subsequent (+)METH intravenous (IV) bolus doses in rats. College on Problems in Drug Dependence, 2004
- Gurley BJ, Gardner SF, Hubbard MA, Williams K, **Gentry B**, Carrier J, Edwards D, and Khan I. Assessment of botanical supplementation on human cytochrome P450 phenotype: citrus aurantium, echinacea, milk thistle, saw palmetto. *Clin. Pharmacol Ther.* 2004; 75:P35.
- Gurley BJ, Gardner SF, Hubbard MA, Williams DK, **Gentry WB**. Effect of botanical supplementation on cytochrome P450 phenotypes in the elderly. *Clin. Pharmacol Ther.* 2005; 77(2):P16
- Gurley BJ, Gardner SF, Williams DK, **Gentry WB**, Hubbard MA, Khan IA, Shah A. Effect of goldenseal, black cohosh, kava kava, and valerian on human cytochrome p450 1A2, 2D6, 2E1, and 3A4 phenotypes. *Clin. Pharmacol Ther.* 2005; 77(2):P36
- Laurenzana EM, Ali S, Gentry WB, Owens SM. Anti-Phencyclidine Monoclonal Antibody (Anti-Pcp Mab) Provides Protection Against Acute And Chronic PCP. Program No. 227.2. 2005 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2005. Online
- Atkinson TN, Pearson C, Barrett TG **Gentry WB**, Gilleland DS. The Research Administrative Norm Indicator (RANI): A New Instrument for Assessing Institutional Professional Conduct in the University Research Administration Profession. American Educational Research Associates Annual Meeting. Chicago, Illinois. April 2007
- Gentry WB**, Mancino M, Oliveto A. Differential effects of abrupt methamphetamine abstinence on mood, cognition and sleep quality in recently abstinent methamphetamine abusers. College on Problems in Drug Dependence Annual Meeting. Quebec City, Canada. June 2007
- Laurenzana EM, **Gentry WB**, Hendrickson HP, Owens SM. New Anti-methamphetamine (METH) **monoclonal** antibodies dramatically alter METH disposition and METH-induced behavioral effects. Presented at ASPET Annual Meeting, San Diego CA 4/6/08
- Hubbard JJ, Laurenzana EM, **Gentry WB**, and Owens SM. Discovery and translational application of pregnancy-related changes in monoclonal antibody pharmacological function in rats. Presented at the National MD/PhD Conference in Keystone, CO. July 18, 2009
- Hubbard J, **Gentry WB** et al. Gestation stage-dependent changes in monoclonal antibody **pharmacological** function during pregnancy in rats. UAMS Student Research Week. April 15 and 16, 2008.
- McGaugh JD, Mancino M, **Gentry W**, Chopra M, Cargile C and Oliveto A. Open label modafinil for methamphetamine dependence: Safety and tolerability College on Problems in Drug Dependence Annual Meeting. San Juan, PR. June 2008
- Ianov I, Barnes IL, **Gentry WB**, Chakraborty I, Khalil R. Extra uterine pregnancy: A case presentation. Presented at the American Society of Anesthesiologists Annual Meeting, Orlando, FL. October 19, 2008
- Chakraborty I, Jansen BJ, and **Gentry WB**. Anesthetic Management For Elective Cesarean Section in a Patient with Recent Stroke. Presented at the IARS Annual meeting in San Diego, CA, March 14, 2009.
- White SJ, Hendrickson HP, **Gentry WB**, and Owens SM. Maternal Administration of an anti-(+)-methamphetamine/(+)-amphetamine (METH/AMP) monoclonal antibody reduces brain METH and AMP concentrations in pregnant rats. Oral Presentation at the Biology, Behavior and Chemistry Conference (Translational Research in Addiction). March 21, 2009. San Antonio, TX.
- Hubbard JJ, Laurenzana EM, **Gentry WB**, and Owens SM. Monoclonal Antibodies (mAb) in pregnancy; Novel pharmacokinetics and neuroprotection of anti-drug mAb in rats. Presented at the National Keystone Symposium on Antibodies as Drugs, Whistler, BC, Canada. March 25-28, 2009

Frank JC, Laurenzana EM, Owens SM, and **Gentry WB**. New Anti-Methamphetamine (METH) Monoclonal Antibodies (mAb) Effectively Reverse Locomotor Effects of Methamphetamine in Rats. Presented at the UAMS Student Research Week. April 8-9, 2009.

**Gentry WB**, Owens SM, Laurenzana EM. A new broad-spectrum anti-methamphetamine (METH) monoclonal antibody (mAb) reverses acute METH effects in rats. College on Problems in Drug Dependence Annual Meeting, Reno, NV. June 25, 2009